InvestorsHub Logo

Troymister

04/18/23 8:31 PM

#586617 RE: Poor Man - #586607

A not-so-splendid example of Linda's poor communications showing at the annual meeting. This quote is as if one of her colleagues slipped her a piece of paper that read, "Maybe you should tell 'em we think our drug works on cancers, other than brain cancer?"

HappyLibrarian

04/18/23 8:44 PM

#586623 RE: Poor Man - #586607

I actually agree with Ms. Powers on that - a fake partnership where NWBO does almost all the heavy lifting but gets no revenue is not going to be taken by markets as a sign of VP confidence and so we would get all the negatives of running a costly trial on our own and then have to share any benefit. Saying no to partnerships that do not have a fairer distribution of costs etc. makes good sense.

Horseb4CarT

04/18/23 8:44 PM

#586624 RE: Poor Man - #586607

It’s just that LP is discerning and not cow towing (sp?) to BP.

Whether this approach yields more or less remains to be seen.

norisknorewards

04/18/23 9:03 PM

#586635 RE: Poor Man - #586607

You've got to be shorting me!

Wow!

Doc logic

04/18/23 9:06 PM

#586638 RE: Poor Man - #586607

Poor Man -,

NWBO was in no position to sponsor that trial with BMY. Why didn’t BMY just partner with UCLA like Merck did?; ). Maybe big money BMY wasn’t very serious and wanted to tease a cash strapped company with false hope offered to unsuspecting investors to try and create some backlash?; ).
Merck was obviously hoping for more leverage too but alas, to no avail at least with the Jeffries analyst and investors disappointed with combo results from the trial with Moderna.
The word on the street years ago was that NWBO was taking a big gamble but that if they could survive the impact would be felt in a big way. That time is upon us and the average investor does not see it yet. What they see is the impact of manipulation and pit bull longs holding on to their shares through “the process”. Did we have an up day today again?; ). Best wishes.